PT Pyridam Farma Tbk

pyfa

Overview

PYFA Overview

PT Pyridam Farma Tbk is an Indonesia-based pharmaceutical company. The Company is engaged in the production, development, and trade of pharmaceuticals, as well as the trade of medical devices and cosmetics. Its segments include pharmaceutical products, esthetic, and toll manufacturing services; and medical equipments. It offers products across consumer health, pyfaesthetic, sanitizer and antiseptic, sterile/injection, biomedilab, betadine group and guardix, and medical support categories. The consumer health category provides over the counter drugs, including supplements and other preventive products, along with energy drinks and healthy ready-to-drink products. Its pyfaesthetic category includes products, such as Arosa Gel, A-Stark Gel, Hymen Gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb Gel. Its sterile/injection category is focused on injection products. Its biomedilab category provides various medical equipment and tools for hospital laboratories.

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: PYFA

Development
Market Cap.
IDR 556.48Billion

~$35.42M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

PYFA Valuation Metrics

1,040

IDR

Closing Price on 2024-04-05

Price to Equity

-9.43

P/E

At -9.43x P/E TTM, PYFA.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Book

1.40

P/B

At 1.40x P/B TTM, PYFA.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Price to Sales

0.81

P/S

At 0.81x P/S TTM, PYFA.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Valuing PT Pyridam Farma Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Pyridam Farma Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
3.41x
Price/Forward Earnings
-
Enterprise Value/Revenue
2.08x
Enterprise Value/EBITDA
54.77x
PEG Ratio
0.09x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR1,0402024-04-05
IDR 2,631.87

Considerably Higher Intrinsic Value: Analyst's intrinsic value is of PYFA is IDR2,632, which is 154% higher than PYFA's last closing price of IDR1,040 (as of 2024-04-05).

Valuation Recap of PYFA stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of -9.43x is below the ID market average of 8.22x and is trading at a discount to peers in the Pharmaceuticals & Health Care Research sector (8.87x). In fact, less than 25% of its peers trade at a lower P/E ratio than PYFA.●●●
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 1.40x is similar to the peers average of 1.29x in the Pharmaceuticals & Health Care Research sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.81x is similar to the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of PYFA's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. PYFA's P/CF ratio of 3.41x is considered healthy by analysts.●●
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. PYFA's EV/R ratio of 2.08x is considered fairly underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.40x.
Max 3
Medium
Considerably Higher Intrinsic Value: Analyst's intrinsic value is of PYFA is IDR 2,631.87, which is 154% higher than PYFA's last closing price of IDR 1,040.00.●●●
Max 3

Peers

PYFA Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
KAEFKimia Farma Tbk.5.04T8.99T 10.19T -0.17T -30.26
Competitiveness Recap of PYFA stock
WeightNotesScore
High
At a market cap of IDR 556.48 billion, PYFA.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of -9.43, PYFA.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -21.00 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of -9.43, PYFA.JK is trading at a lower PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 8.87). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.
Max 2
Medium
At a revenue of IDR 0.68 trillion, PYFA.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of -IDR 0.06 trillion, PYFA.JK ranks 10 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of PYFA

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are shrinking at a projected rate of -1.18% against the IDX average of +12.0%.

Pharmaceuticals & Health Care Research sector overview
No data is available for PYFA at the moment.
Future growth prospect of PYFA
WeightNotesScore
High
PYFA's projected growth rate of -1.18% is below the ID market average of 11.98%.●●●
Max 3
High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 11.14% in 2024. This number is higher than the previous year 2023's growth rate of 2.48%. This bodes well for PYFA's revenue growth prospects in the next 2 years. ●●
Max 3
Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 2.56% in 2024. This number is higher than the previous year 2023's EPS growth of -8.71%. false
Max 3
Medium
PYFA and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for PYFA's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Lee Yan Gwan15.2 years
Dr. (Paulus) Widjanarko Brotosaputro
Director
Yenfrino Gunadi
Director
Bedjo Stefanus
Director
NamePositionShares%
No data is available for PYFA at the moment.
Expressed in millions IDR, unless otherwise stated

Ownership

PYFA Ownership

Others
28.34%
Insiders
63.92%
Institutions
7.74%
NameNumber of SharesOwnership (%)Value
Rejuve Global Investment Pte Ltd216,582,20640.48225.25B
Public (Scripless)149,770,67427.99155.76B
Pt. Aldiracita Sekuritas Indonesia97,795,90618.27101.71B
Dbs Bank Ltd Sg-Pb Clients41,441,3027.7543.10B
Pt. Global Investment Institusi29,429,4005.530.61B
Public (Scrip)60,5120.010.06B
No data is available for PYFA at the moment.